MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial aims were being To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory g... https://lucianol765xis8.goabroadblog.com/profile